The dysregulation of a subset of microRNAs in triple-negative breast cancer is associated with poor survival following neoadjuvant chemotherapy
DOI:
https://doi.org/10.29289/2594539420260018Keywords:
triple-negative breast neoplasms, neoadjuvant therapy, microRNAsAbstract
Introduction: Triple-negative breast cancer (TNBC) is a highly aggressive breast cancer subtype characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. Despite significant research efforts, current therapies are often ineffective against TNBC, resulting in poor survival rates. Therefore, identifying novel molecular markers to predict the response to neoadjuvant chemotherapy (NAC) is essential. MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression and play crucial roles in various biological processes, including cancer progression. This study aimed to investigate the expression of five miRNAs (miR-26a, miR-125b, miR-181c, miR-181a, and miR-340-5p) in formalin-fixed, paraffin-embedded (FFPE) samples from 20 patients with TNBC and to evaluate their association with clinicopathological features. Methods: miRNAs were isolated from FFPE samples of TNBC patients, and their expression levels were assessed using qRT-PCR. An interactive network-based pathway analysis was performed using IPA software to identify key targets regulated by these miRNAs. Results: Our findings revealed the downregulation of miR-181a, miR-181c, miR-26a, and miR-340-5p in patients who subsequently received NAC using the AC-T regimen. Notably, higher expression levels of these miRNAs were associated with improved overall survival, as demonstrated by Kaplan–Meier survival analysis. Additionally, the pathway analysis identified 17 potential targets regulated by miR-340-5p. Conclusion: Taken together, these findings suggest that the downregulation of specific miRNAs in samples from patients with TNBC may serve as a potential biomarker for predicting the response to NAC.
Downloads
References
1. Sathipati SY, Ho SY. Identifying a miRNA signature for predicting the stage of breast cancer. Sci Rep. 2018;8(1):16138. https://doi.org/10.1038/s41598-018-34604-3
2. Verma VK, Beevi SS, Nair RA, Kumar A, Kiran R, Alexander LE, et al. MicroRNA signatures differentiate types, grades, and stages of breast invasive ductal carcinoma (IDC): miRNA-target interacting signaling pathways. Cell Commun Signal. 2024;22(1):100. https://doi.org/10.1186/s12964-023-01452-2
3. Kumar V, Gautam M, Chaudhary A, Chaurasia B. Impact of three miRNA signature as potential diagnostic marker for triple negative breast cancer patients. Sci Rep. 2023;13(1):21643. https://doi.org/10.1038/s41598-023-48896-7
4. Borsos BN, Páhi ZG, Ujfaludi Z, Sükösd F, Nikolényi A, Bankó S, et al. BC-miR: Monitoring Breast Cancer-Related miRNA Profile in Blood Sera-A Prosperous Approach for Tumor Detection, Cells. 2022;11(17):2721. https://doi.org/10.3390/cells11172721
5. Lawson DA, Kessenbrock K, Davis RT, Pervolarakis N, Werb Z. Tumour heterogeneity and metastasis at single-cell resolution. Nat Cell Biol. 2018;20(12):1349-60. https://doi.org/10.1038/s41556-018-0236-7
6. Hsu JY, Chang CJ, Cheng JS. Survival, treatment regimens and medical costs of women newly diagnosed with metastatic triple-negative breast cancer. Sci Rep. 2022;12(1):729. https://doi.org/10.1038/s41598-021-04316-2
7. Han HS, Vikas P, Costa RLB, Jahan N, Taye A, Stringer-Reasor EM. Early-stage triple-negative breast cancer journey: beginning, end, and everything in between. Am Soc Clin Oncol Educ Book. 2023;43:e390464. https://doi.org/10.1200/edbk_390464
8. Zhang Z, Zhang H, Yu J, Xu L, Pang X, Xiang Q, et al. miRNAs as therapeutic predictors and prognostic biomarkers of neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2022;194(3):483-505. https://doi.org/10.1007/s10549-022-06642-z
9. Nariman-Saleh-Fam Z, Saadatian Z, Daraei A, Mansoori Y, Bastami M, Tavakkoli-Bazzaz J. The intricate role of miR-155 in carcinogenesis: potential implications for esophageal cancer research. Biomark Med. 2019;13(2):147-59. https://doi.org/10.2217/bmm-2018-0127
10. Chi LH, Cross RSN, Redvers RP, Davis M, Hediyeh-Zadeh S, Mathivanan S, et al. MicroRNA-21 is immunosuppressive and pro-metastatic via separate mechanisms. Oncogenesis. 2022;11(1):38. https://doi.org/10.1038/s41389-022-00413-7
11. Muñoz JP, Pérez-Moreno P, Pérez Y, Calaf GM. The role of micrornas in breast cancer and the challenges of their clinical application. Diagnostics (Basel). 2023;13(19):3072. https://doi.org/10.3390/diagnostics13193072
12. Bustos MA, Yokoe T, Shoji Y, Kobayashi Y, Mizuno S, Murakami T, et al. MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer. Cell Biosci. 2023;13(1):200. https://doi.org/10.1186/s13578-023-01151-y
13. Santana TABS, Passamai LO, Miranda FS, Borin TF, Borges GF, Luiz WB, et al. The Role of miRNAs in the Prognosis of Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis. Diagnostics (Basel). 2022;13(1):127. https://doi.org/10.3390/diagnostics13010127
14. Zhang Y, Lv L, Zheng R, Xie R, Yu Y, Liao H, et al. Transcriptionally regulated miR-26a-5p may act as BRCAness in Triple-Negative Breast Cancer. Breast Cancer Res. 2023;25(1):75. https://doi.org/10.1186/s13058-023-01663-y
15. Liu B, Su F, Chen M, Li Y, Qi X, Xiao J, et al. Serum miR-21 and miR-125b as markers predicting neoadjuvant chemotherapy response and prognosis in stage II/III breast cancer. Hum Pathol. 2017;64:44-52. https://doi.org/10.1016/j.humpath.2017.03.016
16. Wang H, Tan G, Dong L, Cheng L, Li K, Wang Z, et al. Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PLoS One. 2012;7(4):e34210. https://doi.org/10.1371/journal.pone.0034210
17. Raychaudhuri M, Bronger H, Buchner T, Kiechle M, Weichert W, Avril S. MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2017;162(3):511-21. https://doi.org/10.1007/s10549-017-4132-9
18. Rezaei Z, Sebzari A, Kordi-Tamandani DM, Dastjerdi K. Involvement of the Dysregulation of miR-23b-3p, miR-195-5p, miR-656-5p, and miR-340-5p in Trastuzumab Resistance of HER2-Positive Breast Cancer Cells and System Biology Approach to Predict Their Targets Involved in Resistance. DNA Cell Biol. 2019;38(2):184-92. https://doi.org/10.1089/dna.2018.4427
19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-8. https://doi.org/10.1006/meth.2001.1262
20. Braga LC, Goncalves BOP, Coelho PL, Silva Filho AL, Silva LM. Identification of best housekeeping genes for the normalization of RT-qPCR in human cell lines. Acta Histochem. 2022;124(1):151821. https://doi.org/10.1016/j.acthis.2021.151821
21. Gonçalves BOP, Andrade WP, Fialho SL, Silva LM. Markers to sensibility and relapse on IMR-32 neuroblastoma cell line cultured in monolayer (2D) and neurosphere (3D) models cisplatin-treated. Acta Histochem. 2022;124(2):151849. https://doi.org/10.1016/j.acthis.2022.151849
22. Lima AB, Gonçalves BOP, Moreira MP, Barros BAF, Silva Filho AL, Fialho SL, et al. Ovarian cancer cell heterogeneity and paclitaxel response in vitro 2D and 3D cancer cell models and xenograft growth in the chicken chorioallantoic membrane (CAM). Biochem Biophys Res Commun. 2025;777:152322. https://doi.org/10.1016/j.bbrc.2025.152322
23. Gonçalves BOP, Almeida MR, Costa VV, Del Puerto HL, Birbrair A, Lopes LMS. Cisplatin treatment induces a shift toward a quiescent Ki-67(-)/CD44(+)/CD133(+) cancer stem cell subpopulation in a tumorsphere model derived from a murine non-small cell lung cancer cell line. Acta Histochem. 2026;128(1):152313. https://doi.org/10.1016/j.acthis.2025.152313
24. Song L, Duan P, Gan Y, Li P, Zhao C, Xu J, et al. MicroRNA-340-5p modulates cisplatin resistance by targeting LPAATbeta in osteosarcoma. Braz J Med Biol Res. 2017;50(5):e6359. https://doi.org/10.1590/1414-431x20176359
25. Huang Z, Xu Y, Wan M, Zeng X, Wu J. miR-340: A multifunctional role in human malignant diseases. Int J Biol Sci. 2021;17(1):236-46. https://doi.org/10.7150/ijbs.51123
26. Algaber A, Al-Haidari A, Madhi R, Rahman M, Syk I, Thorlacius H. MicroRNA-340-5p inhibits colon cancer cell migration via targeting of RhoA. Sci Rep. 2020;10(1):16934. https://doi.org/10.1038/s41598-020-73792-9
27. Wang Y, Tahiri H, Yang C, Gu M, Ruan X, Hardy P. Overexpression of miR-181a regulates the Warburg effect in triple-negative breast cancer. Climacteric. 2023;26(1):64-71. https://doi.org/10.1080/13697137.2022.2147821
28. Gonçalves BÔP, Fialho SL, Silvestrini BR, Sena IFG, Dos Santos GSP, Gomes DA, et al. Central nervous system (CNS) tumor cell heterogeneity contributes to differential platinum-based response in an in vitro 2D and 3D cell culture approach. Exp Mol Pathol. 2020;116:104520. https://doi.org/10.1016/j.yexmp.2020.104520
29. Gonçalves BÔP, Andrade WP, Braga LC, Fialho SL, Silva LM. Epithelial-to-mesenchymal transition markers are differentially expressed in epithelial cancer cell lines after everolimus treatment. Oncol Lett. 2020;20(5):158. https://doi.org/10.3892/ol.2020.12019
30. Gonçalves BÔP, Santos GSP, Andrade WP, Fialho SL, Gomes DA, Silva LM. Phenotypic changes on central nervous system (CNS) tumor cell lines cultured in vitro 2D and 3D models and treated with cisplatin. Acta Histochem. 2021;123(6):151768. https://doi.org/10.1016/j.acthis.2021.151768
31. Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20(2):69-84. https://doi.org/10.1038/s41580-018-0080-4
32. Kim DH, Xing T, Yang Z, Dudek R, Lu Q, Chen YH. Epithelial Mesenchymal Transition in Embryonic Development, Tissue Repair and Cancer: A Comprehensive Overview. J Clin Med. 2017;7(1):1. https://doi.org/10.3390/jcm7010001
33. Zhang B, Wang E, Zhou S, Han R, Wu W, Sun G, et al. RELA-mediated upregulation of LINC03047 promotes ferroptosis in silica-induced pulmonary fibrosis via SLC39A14. Free Radic Biol Med. 2024;223:250-62. https://doi.org/10.1016/j.freeradbiomed.2024.08.002
34. Xia C, Zhang XY, Liu W, Ju M, Ju Y, Bu YZ, et al. LINC00857 contributes to hepatocellular carcinoma malignancy via enhancing epithelial-mesenchymal transition. J Cell Biochem. 2019;120(5):7970-7. https://doi.org/10.1002/jcb.28074
35. Tang S, Liu Q, Xu M. LINC00857 promotes cell proliferation and migration in colorectal cancer by interacting with YTHDC1 and stabilizing SLC7A5. Oncol Lett. 2021;22(2):578. https://doi.org/10.3892/ol.2021.12839
36. Ciardiello F, Kim N, McGeady ML, Liscia DS, Saeki T, Bianco C, et al. Expression of transforming growth factor alpha (TGF alpha) in breast cancer. Ann Oncol. 1991;2(3):169-82. https://doi.org/10.1093/oxfordjournals.annonc.a057897
37. Humphreys RC, Hennighausen L. Transforming growth factor alpha and mouse models of human breast cancer. Oncogene. 2000;19(8):1085-91. https://doi.org/10.1038/sj.onc.1203278
38. Huang CY, Hsieh NT, Li CI, Weng YT, Liu HS, Lee MF. MED28 Regulates Epithelial-Mesenchymal Transition Through NFkappaB in Human Breast Cancer Cells. J Cell Physiol. 2017;232(6):1337-45. https://doi.org/10.1002/jcp.25610
39. Gonçales NG, Gonçalves BÔP, Silva LM, Silva Filho AL, Braga LC. TNFRSF10D expression as a potential biomarker for cisplatin-induced damage and ovarian tumor relapse prediction. Pathol Res Pract. 2024;263:155592. https://doi.org/10.1016/j.prp.2024.155592
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Bryan Ôrtero Perez Gonçalves, Bárbara Danielle Silva Siqueira, Fábio Ribeiro Queiroz, Clécio Ênio Murta de Lucena, Ana Luiza de Freitas Magalhães Gomes, Paulo Guilherme de Oliveira Salles, Luciana Maria Silva, Letícia da Conceição Braga
This work is licensed under a Creative Commons Attribution 4.0 International License.
